Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Dan - what is going on?!

<< Previous

Bullboard Posts

Next >>

Post by Yellowknifer69on Jan 25, 2021 11:14am

378 Views

Post# 32375254

Dan - what is going on?!

Hey Dan , Where is the news brief?

Oh Brother Dan where art thou? (sorry, been trying to teach myself to play the banjo.)

So coming on 12th week since last news? Must be a record over the past 2 years for ATE.

I see that Merck is getting out of the Covid vaccine business. Anybody know if they have any cash for new pipeline ventures?

All right, I got nothing else except we are finally starting to vaccinate our elders! Hopefully the day comes when we can get back to some semblance of normalcy.

Take care and staying long on ATE -

Yellowknifer

<< Previous

Bullboard Posts

Next >>

Nvidia reports record revenue in Q3